- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02278718
A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care
A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A total of 160 patients will be randomized into NexoBrid and SOC treatment (80 patients per arm).
Age distribution will be managed as follows:
- 45 patients 0-23 months old
- 45 patients 24 months-3 years old
- 30 patients 4-11 years old
- 20 patients 12-17 years old The remaining 20 patients will be enrolled to any of the above groups, per their age during enrollment.
The study will be conducted in three stages. In Stage I, at least 24 children age 4-18 years, hospitalized in burn units, with deep partial thickness burns ranging from 1%-30% TBSA, and who meet the entrance criteria, will be enrolled. Upon completion of stage I, a safety analysis will be performed on safety parameters and the results will be evaluated by a Data Safety Monitoring Board (DSMB) as defined in the agreed charter. If the DSMB does not have any safety concerns, Stage II will commence, this time enrolling at least 26 additional children aged of 1-18 years according to the study procedures. A DSMB will be convened to assess the safety data of the first 50 patients enrolled at stages 1 & 2. If the DSMB has not found any safety concerns, stage III will commence in which patients from the age of birth to 18 years will be included (stage III will include 110 remaining patients required to reach a total of 160 patients).
Following the enrollment of a subject to the study and prior to randomization, physicians will define one or more Target Wounds (TWs) per subject according to TWs definition. All subjects' DPT and FT burns that fit the specified criteria are intended to receive study treatment per randomized study arm and therefore, must be designated as TWs.
Prior to eschar removal treatment with NexoBrid or SOC subjects will be medicated with appropriate analgesia and undergo wound cleansing and dressing of all wounds with antibacterial solutions. Following wound cleansing and antibacterial treatments, subjects will undergo the eschar removal process as per treatment assignment (NexoBrid or SOC, following randomization). Subsequent to eschar removal, all wounds will be assessed and treated in the same manner, in accordance with post-eschar removal wound care strategy. Furthermore, subjects will undergo daily assessments (Vital signs (VS) and pain assessments) for one week and weekly assessments thereafter, until wound closure. Following wound closure, subjects will be followed up at 6 weeks, 12 weeks, and after that, at 6, 12, 18 and 24 months (for a blinded assessment of cosmesis, function and QoL evaluation).
All subjects will be invited to one additional extended follow up visit that will occur at least 30 months after wound closure confirmation for a blinded assessment of cosmesis, function and QoL evaluation.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Gent, Belgium, B 9000
- University Hospital, Department of Plastic Surgery
-
-
-
-
-
Tbilisi, Georgia, 0179
- S. Khechinashvili University Hospital
-
-
-
-
-
Berlin, Germany, 12683
- Unfallkrankenhaus Berlin Zentrum für Schwerbrandverletzte mit Plastischer Chirurgie
-
Stuttgart, Germany, D-70176
- Klinikum Stuttgart - Olgahospital
-
-
-
-
-
Budapest, Hungary, H-1146
- MRE Bethesda Gyermekkórháza
-
Miskolc, Hungary, H-3526
- B.A.Z Megyei Kórház és Egyetemi Oktatókórház
-
Pécs, Hungary, H-7624
- Klinikai Kozpont Gyermekgyogyaszati Klinika
-
-
-
-
-
Mysuru, India, 570001
- Krishna Rajendra Hospital
-
New Delhi, India, 110029
- Vardhman Mahavir Medical College (VLCC) and Safdarjung Hospital
-
-
Delhi
-
New Delhi, Delhi, India, 110001
- Dr. Ram Manohar Lohia Hospital, Baba Kharak Singh Marg
-
-
-
-
-
Verona, Italy, 37126
- Universitary Integrated Hospital Verona (AOUI Verona),
-
-
-
-
-
Beverwijk, Netherlands, 1942
- Acute Burn Care &Trauma Surgery, Dept Surgery/Burn Center, Rode Kruis Ziekenhuis, LUMC University Leiden
-
-
-
-
-
Kraków, Poland, 30-663
- Uniwersytecki Szpital Dziecięcy w Krakowie
-
Warszawa, Poland
- Szpital Dzieciecy im.prof.dr.med Jana Bogdanowicza, Oddzial Chirurgii i Urologii Dzieciecej z Pododdzialem Leczenia Oparzen
-
-
-
-
-
Iasi, Romania, 700309
- Spitalul Clinic de Urgenta pentru Copii "Sfanta Maria"
-
Târgu-Mureş, Romania, 54000
- Spitalul Clinic de Urgenta Tg- Mures
-
-
-
-
-
Bratislava, Slovakia, 826 06
- Univerzitná nemocnica Bratislava, Klinika popálenin a rekonštrukčnej chirurgie
-
-
-
-
-
Madrid, Spain, 28046
- La Paz University Hospital
-
Valencia, Spain, 46026
- Boulevar Sur s/n
-
-
-
-
-
Kharkiv, Ukraine, 61103
- CNPE "City clinical hospital of immediate and urgent medical aid n.a.Meshchaninov" of Kharkiv CC and State institution 'Zaitsev V.T. Institute of general and urgent surgery of the National academy of medical sciences of Ukraine'
-
Odesa, Ukraine, 65049
- Communal institution "Odessa Regional Clinical Medical Center"
-
-
-
-
-
Birmingham, United Kingdom
- Birmingham Children´s Hospital NHS Foundation Trust
-
Manchester, United Kingdom, M13 9WL
- Royal Manchester Children's Hospital
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85008
- Maricopa Special Health Care District
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
Miami, Florida, United States, 33146
- University of Miami
-
Tampa, Florida, United States, 33620
- The University of South Florida Board of Trustees
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- University of Kansas Medical Center Research Institute, Inc.
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Shriners Hospital for Children
-
-
New York
-
Stony Brook, New York, United States, 11794
- Stony Brook University Medical Center
-
-
Oregon
-
Portland, Oregon, United States, 97232
- Legacy Emanuel Hospital & Health Center dba Legacy Research Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19134
- Drexel University
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425s
- Shawn Jekins Children's Hospital
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah
-
-
Washington
-
Seattle, Washington, United States, 98104
- Harborview Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Stage 1: Males and females between 4 years to 18 years of age, Stage 2 (upon DSMB review): Males and females between 1 year to 18 years of age, Stage 3 (upon DSMB review): Males and females between 0 years to 18 years of age.
- Thermal burns caused by fire/flame, scalds or contact.
- Patient total burns area ≥ 1% DPT and / or FT,
- Patient total burns area should be ≤ 30% TBSA; SPT, DPT and/or FT in depth,
- Signed written informed consent by a legal guardian can be obtained within 84 hours of the burn injury.
At least one wound (a continuous burn area which can be treated in one session; might include several anatomical areas) in a patient should meet all following criteria:
- Wound that is ≥ 1% TBSA (DPT and/or FT) (not including face, perineal or genital),
- Wound is composed of DPT and/or FT in depth. Superficial partial thickness areas may be included in the wound area only if cannot be separated from deeper areas (e.g. surrounded by or mixed with DPT areas) and might interfere with the treatment of the deeper areas,
- Wound that is potentially intended for surgical eschar removal,
- Wound's blisters can be unroofed, as judged by the investigator.
Exclusion Criteria:
- Patients weighing less than 3kg,
- Patients who are unable to follow study procedures and follow up period,
- Patients with electrical or chemical burns,
- Patient with a continuous burn area above 15% TBSA,
- Patients with no DPT and/or FT burn area (only SPT wounds),
- Patient with circumferential anterior/posterior trunk fire/flame burns, >15% TBSA (Circumferential is defined as encircling ≥ 80% of the trunk circumference),
- The following pre-enrolment dressings: a. Flammacerium, b. Silver Nitrate (AgNO3),
- Patients with diagnosed infections,
- Diagnosis of smoke inhalation injury,
- Patients with pre-enrolment wounds which are covered by eschar saturated with iodine or by SSD pseudoeschar (e.g. pseudoeschar as a result of >12h SSD treatment),
- Patients with pre-enrolment escharotomy,
- Pregnant women (positive pregnancy test) or nursing mothers,
- Poorly controlled diabetes mellitus (HbA1c>9%),
- Known Cardio-pulmonary disease, oxygen-dependent pulmonary diseases, broncho-pneumonia, uncontrolled asthma,
- Known conditions which interfere with circulation (peripheral vascular disease, edema, lymphedema, surgery to the regional lymph nodes, obesity),
- Any known conditions that would preclude safe participation in the study or adding further risk to the basic acute burn trauma (such as immuno-compromising diseases, life threatening trauma, severe pre-existing coagulation disorder, pulmono-cardiovascular, liver or neoplastic disease),
- ASA greater than 2
- Chronic systemic steroid intake,
- History of allergy and/or known sensitivity to pineapples, papaya, Bromelain or papain,
- Current (within 12 months prior to screening) suicide attempt,
- Enrollment in any investigational drug trial within 4 weeks prior to screening,
- Current (within 12 months prior to screening) alcohol (daily consumption > 3 units for males and >2 units for females) or drug abuse,
- Prisoners and incarcerated
- Patients who might depend on the clinical study site or investigator.
- Patient expresses objection to participate in the study.
- Patients with other severe cutaneous trauma at the same sites as the burns (i.e. blunt, avulsion or deep abrasion) or previous burn(s) at the same treatment site(s)
- General condition of patient would contraindicate surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NexoBrid Gel
NexoBrid Gel is applied to the burn wound at a dose of 2g or 5g NexoBrid sterile powder mixed with 20g or 50g sterile Gel Vehicle per 180cm^2 of TBSA for four hours.
|
NexoBrid is an enzymatic debriding agent for Eschar Removal.
|
Active Comparator: Standard of Care
Non surgical and Surgical Debridement
|
Surgical or Non-Surgical methods for Eschar Removal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Earlier eschar removal (in days)
Time Frame: participants will be followed from randomization date and daily for the duration of hospital stay, an expected average of 3 weeks
|
Demonstrate superiority over SOC for eschar removal as measured by a survival analysis of incidence of complete eschar removal as a function of time.
Eschar removal will be measured at the end of the debridement starting from randomization date.
|
participants will be followed from randomization date and daily for the duration of hospital stay, an expected average of 3 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Lior Rosenberg, Prof., MediWound Ltd
- Study Director: Yaron Shoham, Dr., MediWound Ltd
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MW2012-01-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thermal Burns
-
Cairo UniversityCompleted
-
Singapore General HospitalUnknownAcute Thermal BurnsSingapore
-
Cytori TherapeuticsCompleted
-
MediWound LtdCompletedThermal BurnsUnited States, Israel, Belgium, Czechia, Georgia, Germany, Italy, Romania
-
University of FloridaTerminated
-
Stratatech, a Mallinckrodt CompanyActive, not recruitingFull Thickness Thermal BurnUnited States
-
Regeneron PharmaceuticalsSanofiWithdrawnThermal Injury PainUnited States
-
HealthPartners InstituteCompleted
-
Stratatech, a Mallinckrodt CompanyCompleted
-
University of Texas Southwestern Medical CenterWithdrawn
Clinical Trials on NexoBrid
-
MediWound LtdAvailableThermal BurnUnited States
-
MediWound LtdCompletedThermal BurnsUnited States, Israel, Belgium, Czechia, Georgia, Germany, Italy, Romania